Debbie S Gipson

List of Publications by Year
in descending order

153 papers	7,838 citations	57758 44 h-index	56724 83 g-index
154 all docs	154 docs citations	154 times ranked	8039 citing authors

#	Article	IF	Citations
1	US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 2019, 73, A7-A8.	1.9	680
2	US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 2015, 66, A7.	1.9	484
3	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney International, 2013, 83, 749-756.	5.2	268
4	Management of Childhood Onset Nephrotic Syndrome. Pediatrics, 2009, 124, 747-757.	2.1	247
5	A phase 1, single-dose study of fresolimumab, an anti-TGF-Î² antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney International, 2011, 79, 1236-1243.	5.2	222
6	Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatric Nephrology, 2013, 28, 415-426.	1.7	218
7	Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney International, 2011, 80, 868-878.	5.2	208
8	Anthropometric measures and risk of death in children with end-stage renal disease. American Journal of Kidney Diseases, 2000, 36, 811-819.	1.9	204
9	Circulating suPAR in Two Cohorts of Primary FSGS. Journal of the American Society of Nephrology: JASN, 2012, 23, 2051-2059.	6.1	202
10	Validation of the KDIGO acute kidney injury criteria in a pediatric critical care population. Intensive Care Medicine, 2014, 40, 1481-1488.	8.2	188
11	Health-Related Quality of Life of Children With Mild to Moderate Chronic Kidney Disease. Pediatrics, 2010, 125, e349-e357.	2.1	182
12	IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatric Nephrology, 2020, 35, 1529-1561.	1.7	179
13	Neurocognitive Functioning of Children and Adolescents with Mild-to-Moderate Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1824-1830.	4.5	150
14	Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method. Quality of Life Research, 2016, 25, 13-23.	3.1	148
15	A Clinical Tool to Measure the Components of Health-Care Transition from Pediatric Care to Adult Care: TheUNC TR_xANSITION Scale. Renal Failure, 2012, 34, 744-753.	2.1	146
16	Differential risk of remission and ESRD in childhood FSGS. Pediatric Nephrology, 2006, 21, 344-349.	1.7	128
17	DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. Journal of the American Society of Nephrology: JASN, 2018, 29, 2745-2754.	6.1	128
18	Association of Histologic Variants in FSGS Clinical Trial with Presenting Features and Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 399-406.	4.5	125

#	Article	IF	Citations
19	HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2015, 26, 1701-1710.	6.1	118
20	Trends in treatment and outcomes of survival of adolescents initiating end-stage renal disease care in the United States of America. Pediatric Nephrology, 2006, 21, 1020-1026.	1.7	115
21	A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney International, 2015, 87, 564-574.	5.2	111
22	The Impact of Short Stature on Health-Related Quality of Life in Children with Chronic Kidney Disease. Journal of Pediatrics, 2013, 163, 736-741.e1.	1.8	109
23	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. Journal of the American Society of Nephrology: JASN, 2015, 26, 1443-1448.	6.1	104
24	Memory and Executive Functions in Pediatric Chronic Kidney Disease. Child Neuropsychology, 2006, 12, 391-405.	1.3	92
25	Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatric Nephrology, 2013, 28, 409-414.	1.7	91
26	GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. American Journal of Kidney Diseases, 2018, 72, 519-528.	1.9	82
27	Clinical predictors of neurocognitive deficits in children with chronic kidney disease. Pediatric Nephrology, 2007, 22, 565-572.	1.7	78
28	Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease. JAMA Cardiology, 2019, 4, 353.	6.1	77
29	Casual Blood Pressure and Neurocognitive Function in Children with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1831-1837.	4.5	74
30	Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group. American Journal of Kidney Diseases, 2010, 55, 50-60.	1.9	73
31	Brief Report: Intellectual and Academic Functioning in Pediatric Chronic Kidney Disease. Journal of Pediatric Psychology, 2007, 32, 1011-1017.	2.1	72
32	Predictors of Relapse and End Stage Kidney Disease in Proliferative Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1962-1967.	4.5	69
33	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	1.9	68
34	Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrology, 2015, 16, 111.	1.8	63
35	Cognitive improvement in children with CKD after transplant. Pediatric Transplantation, 2010, 14, 887-890.	1.0	61
36	Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrologyâ€"Children and Adolescents (SONG-KIDS) consensus workshops. Kidney International, 2020, 98, 553-565.	5.2	58

#	Article	IF	Citations
37	An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 414-421.	4.5	57
38	Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS ONE, 2015, 10, e0136558.	2.5	54
39	Complete Remission in the Nephrotic Syndrome Study Network. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 81-89.	4.5	53
40	Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney International, 2011, 79, 678-685.	5.2	52
41	Gaining the PROMIS perspective from children with nephrotic syndrome: a Midwest pediatric nephrology consortium study. Health and Quality of Life Outcomes, 2013, 11, 30.	2.4	51
42	The relatively poor correlation between random andÂ24-hour urine protein excretion in patients withÂbiopsy-proven glomerular diseases. Kidney International, 2016, 90, 1080-1089.	5.2	51
43	The impact of disease duration on quality of life in children with nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatric Nephrology, 2015, 30, 1467-1476.	1.7	49
44	Prevalence of sleep disturbances in children and adolescents with chronic kidney disease. Pediatric Nephrology, 2012, 27, 451-459.	1.7	48
45	The central nervous system in childhood chronic kidney disease. Pediatric Nephrology, 2007, 22, 1703-1710.	1.7	47
46	Gaining the Patient Reported Outcomes Measurement Information System (PROMIS) perspective in chronic kidney disease: a Midwest Pediatric Nephrology Consortium study. Pediatric Nephrology, 2014, 29, 2347-2356.	1.7	47
47	Management patterns of childhood-onset nephrotic syndrome. Pediatric Nephrology, 2009, 24, 2193-2201.	1.7	46
48	Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study. American Journal of Kidney Diseases, 2018, 72, 547-559.	1.9	46
49	Assessing responsiveness over time of the PROMISÂ® pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease. Quality of Life Research, 2018, 27, 249-257.	3.1	45
50	Recent Trends in Healthcare Utilization Among Children and Adolescents With Hypertension in the United States. Hypertension, 2012, 60, 296-302.	2.7	42
51	Identifying Important Outcomes for Young People With CKD and Their Caregivers: A Nominal Group Technique Study. American Journal of Kidney Diseases, 2019, 74, 82-94.	1.9	42
52	Standardised Outcomes in Nephrologyâ€"Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. Trials, 2016, 17, 401.	1.6	41
53	Soluble ST2 and Galectin-3 and Progression of CKD. Kidney International Reports, 2019, 4, 103-111.	0.8	41
54	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39

#	Article	IF	Citations
55	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38
56	The nervous system and chronic kidney disease in children. Pediatric Nephrology, 2004, 19, 832-9.	1.7	36
57	Inpatient Health Care Utilization in the United States Among Children, Adolescents, and Young Adults With Nephrotic Syndrome. American Journal of Kidney Diseases, 2013, 61, 910-917.	1.9	36
58	Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET). Kidney International Reports, 2017, 2, 654-664.	0.8	36
59	Range and Heterogeneity of Outcomes in Randomized Trials of Pediatric Chronic Kidney Disease. Journal of Pediatrics, 2017, 186, 110-117.e11.	1.8	35
60	Phase I Trial of Rosiglitazone in FSGS. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 39-47.	4.5	34
61	Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrology, 2011, 12, 8.	1.8	34
62	Neurocognitive, Social-Behavioral, and Adaptive Functioning in Preschool Children with Mild to Moderate Kidney Disease. Journal of Developmental and Behavioral Pediatrics, 2016, 37, 231-238.	1.1	34
63	Implications of different fluid overload definitions in pediatric stem cell transplant patients requiring continuous renal replacement therapy. Intensive Care Medicine, 2012, 38, 663-669.	8.2	33
64	Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study. Journal of the American Society of Nephrology: JASN, 2022, 33, 1193-1207.	6.1	33
65	Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrology, 2010, 11, 2.	1.8	32
66	Gut Microbial Product Predicts Cardiovascular Risk in Chronic Kidney Disease Patients. American Journal of Nephrology, 2018, 48, 269-277.	3.1	32
67	Novel Therapies for FSGS: Preclinical and Clinical Studies. Advances in Chronic Kidney Disease, 2015, 22, e1-e6.	1.4	31
68	The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis. American Journal of Kidney Diseases, 2004, 43, 1082-1090.	1.9	30
69	Brain abnormalities in children and adolescents with chronic kidney disease. Pediatric Research, 2018, 84, 387-392.	2.3	30
70	Therapeutic approach to FSGS in children. Pediatric Nephrology, 2007, 22, 28-36.	1.7	26
71	Treatment of FSGS in Children. Advances in Chronic Kidney Disease, 2014, 21, 194-199.	1.4	26
72	Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease. Bioinformatics, 2019, 35, 3441-3452.	4.1	26

#	Article	IF	Citations
73	Public Participation in, and Awareness about, Medical Research Opportunities in the Era of Clinical and Translational Research. Clinical and Translational Science, 2013, 6, 88-93.	3.1	25
74	Patient-Reported Outcomes in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 140-148.	4.5	24
75	Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatric Nephrology, 2016, 31, 465-472.	1.7	23
76	Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis. American Journal of Kidney Diseases, 2021, 77, 216-225.	1.9	23
77	Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium. Pediatric Nephrology, 2013, 28, 1235-1241.	1.7	22
78	Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome. Kidney International Reports, 2018, 3, 115-121.	0.8	21
79	Contribution of Renal and Nonâ€Renal Clearance on Increased Total Clearance of Adalimumab in Glomerular Disease. Journal of Clinical Pharmacology, 2013, 53, 919-924.	2.0	20
80	Development of a Pediatric Adverse Events Terminology. Pediatrics, 2017, 139, .	2.1	20
81	Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease. Kidney International Reports, 2019, 4, 1608-1616.	0.8	20
82	Socialâ€behavioural functioning in paediatric chronic kidney disease. Child: Care, Health and Development, 2009, 35, 832-840.	1.7	19
83	Renal Function and Proteinuria after Successful Immunosuppressive Therapies in Patients with FSGS. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 211-218.	4.5	19
84	Responsiveness of the PROMISÂ® measures to changes in disease status among pediatric nephrotic syndrome patients: a Midwest pediatric nephrology consortium study. Health and Quality of Life Outcomes, 2017, 15, 166.	2.4	19
85	A longitudinal examination of parent-reported emotional-behavioral functioning of children with mild to moderate chronic kidney disease. Pediatric Nephrology, 2020, 35, 1287-1295.	1.7	19
86	Tryptophan levels associate with incident cardiovascular disease in chronic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 1097-1105.	2.9	19
87	Hypertension and Health Outcomes in the PICU. Pediatric Critical Care Medicine, 2014, 15, 417-427.	0.5	18
88	The Effect of a Gluten-Free Diet in Children With Difficult-to-Manage Nephrotic Syndrome. Pediatrics, 2016, 138, .	2.1	17
89	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.8	17
90	Patient Recruitment into a Multicenter Randomized Clinical Trial â€˜for Kidney Disease: Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS CT). Clinical and Translational Science, 2013, 6, 13-20.	3.1	16

#	Article	IF	Citations
91	Using PROMISÂ® to create clinically meaningful profiles of nephrotic syndrome patients.. Health Psychology, 2019, 38, 410-421.	1.6	16
92	Adult survivors of idiopathic childhood onset nephrotic syndrome. Pediatric Nephrology, 2021, 36, 1731-1737.	1.7	16
93	Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. Kidney International Reports, 2021, 6, 2575-2584.	0.8	15
94	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
95	A unified framework for evaluating the risk of re-identification of text de-identification tools. Journal of Biomedical Informatics, 2016, 63, 174-183.	4.3	14
96	Learning to live with nephrotic syndrome: experiences of adult patients and parents of children with nephrotic syndrome. Nephrology Dialysis Transplantation, 2017, 32, i98-i105.	0.7	14
97	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	2.9	14
98	Unsupervised machine learning for identifying important visual features through bag-of-words using histopathology data from chronic kidney disease. Scientific Reports, 2022, 12, 4832.	3.3	14
99	Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN). Kidney International Reports, 2019, 4, 1725-1734.	0.8	13
100	Patient Engagement in Neurological Clinical Trials Design: A Conference Summary. Clinical and Translational Science, 2015, 8, 776-778.	3.1	12
101	Improving the evidence for the management of childhood nephrotic syndrome. Kidney International, 2017, 92, 21-23.	5.2	12
102	Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire. American Journal of Kidney Diseases, 2017, 70, 532-540.	1.9	12
103	Plasma Zonulin Levels in Childhood Nephrotic Syndrome. Frontiers in Pediatrics, 2019, 7, 197.	1.9	12
104	Inpatient health care utilization by children and adolescents with systemic lupus erythematosus and kidney involvement. Arthritis Care and Research, 2013, 65, 382-390.	3.4	11
105	A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). European Journal of Clinical Pharmacology, 2016, 72, 253-255.	1.9	11
106	Creation of a Multicenter Pediatric Inpatient Data Repository Derived from Electronic Health Records. Applied Clinical Informatics, 2019, 10, 307-315.	1.7	11
107	Neurodevelopmental Status and Adaptive Behaviors in Preschool Children with Chronic Kidney Disease. Journal of Special Education, 2009, 43, 45-51.	1.7	10
108	Optimizing Enrollment of Patients into Nephrology Research Studies. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 512-517.	4.5	10

#	Article	IF	Citations
109	NephCure Accelerating Cures Institute: AÂMultidisciplinary Consortium to Improve Care for Nephrotic Syndrome. Kidney International Reports, 2018, 3, 439-446.	0.8	10
110	Urinary Epidermal Growth Factor as a Marker of Disease Progression in Children With Nephrotic Syndrome. Kidney International Reports, 2020, 5, 414-425.	0.8	10
111	Consent for Genetic Biobanking in a Diverse Multisite CKD Cohort. Kidney International Reports, 2018, 3, 1267-1275.	0.8	9
112	Text Messaging for Disease Monitoring inÂChildhood Nephrotic Syndrome. Kidney International Reports, 2019, 4, 1066-1074.	0.8	9
113	Inpatient Pediatric CKD Health Care Utilization and Mortality in the United States. American Journal of Kidney Diseases, 2021, 77, 500-508.	1.9	9
114	Changing the Paradigm for the Treatment and Development of New Therapies for FSGS. Frontiers in Pediatrics, 2016, 4, 25.	1.9	8
115	Toward Patient-Centered Innovation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1522-1530.	4.5	8
116	A measure of success in kidney transplantations. Pediatric Transplantation, 2004, 8, 104-105.	1.0	7
117	Dynamic treatment regimens in small n, sequential, multiple assignment, randomized trials: An application in focal segmental glomerulosclerosis. Contemporary Clinical Trials, 2020, 92, 105989.	1.8	7
118	Improving data quality in observational research studies: Report of the Cure Glomerulonephropathy (CureGN) network. Contemporary Clinical Trials Communications, 2021, 22, 100749.	1.1	7
119	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.	5.2	7
120	Functional Magnetic Resonance Imaging Findings in Children and Adolescents With Chronic Kidney Disease: Preliminary Findings. Seminars in Nephrology, 2021, 41, 462-475.	1.6	7
121	Regarding Maas's editorial letter on serum suPAR levels. Kidney International, 2012, 82, 492.	5.2	6
122	Validating a Computable Phenotype for Nephrotic Syndrome in Children and Adults Using PCORnet Data. Kidney360, 2021, 2, 1979-1986.	2.1	6
123	Intraperitoneal administration of recombinant human growth hormone in children with end-stage renal disease. Pediatric Nephrology, 2001, 16, 29-34.	1.7	5
124	Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis. Kidney International Reports, 2020, 5, 1228-1239.	0.8	5
125	Pediatric Immunization Practices in Nephrotic Syndrome: An Assessment of Provider and Parental Knowledge. Frontiers in Pediatrics, 2020, 8, 619548.	1.9	5
126	Health-Related Quality of Life in Focal Segmental Glomerular Sclerosis and Minimal Change Disease: A Qualitative Study of Children and Adults to Inform Patient-Reported Outcomes. Kidney Medicine, 2021, 3, 484-497.e1.	2.0	5

#	Article	IF	Citations
127	Pediatric chronic kidney disease in North Carolina. North Carolina Medical Journal, 2008, 69, 208-14.	0.2	5
128	Innovating and invigorating the clinical trial infrastructure for glomerular diseases. Kidney International, 2021, 99, 519-523.	5.2	4
129	A pediatric gateway initiative for glomerular disease: introducing PIONEER. Kidney International, 2021, 99, 515-518.	5.2	4
130	Health-related quality of life in children with chronic kidney disease is affected by the number of medications. Pediatric Nephrology, 2021, 36, 1307-1310.	1.7	4
131	Kidney Injury Molecule-1 and Periostin Urinary Excretion and Tissue Expression Levels and Association with Glomerular Disease Outcomes. Complex Psychiatry, 2021, 1, 45-59.	0.9	4
132	Childhood Onset Nephrotic Syndrome. , 2014, , 23-31.		3
133	Fibroblast growth factorâ€23 and chronic allograft injury in pediatric renal transplant recipients: a Midwest Pediatric Nephrology Consortium study. Pediatric Transplantation, 2016, 20, 378-387.	1.0	3
134	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	1.7	3
135	The Development and Use of an EHR-Linked Database for Glomerular Disease Research and Quality Initiatives. Glomerular Diseases, 2021, 1, 173-179.	1.0	3
136	Perspectives of Clinicians on Shared Decision Making in Pediatric CKD: A Qualitative Study. American Journal of Kidney Diseases, 2022, 80, 241-250.	1.9	3
137	The Health Economic Impact of Nephrotic Syndrome in the United States. Kidney360, 0, , 10.34067/KID.0005072021.	2.1	3
138	Renal Manifestations of Systemic Illness in Children. Seminars in Nephrology, 2009, 29, 360-369.	1.6	2
139	Matching the Genotype in Resolution: Innovative Ways of Phenotype Capture. Seminars in Nephrology, 2015, 35, 279-290.	1.6	2
140	Provider perspectives on treatment decision-making in nephrotic syndrome. Nephrology Dialysis Transplantation, 2017, 32, i106-i114.	0.7	2
141	Time to Initiation of Antihypertensive Therapy After Onset of Elevated Blood Pressure in Patients With Primary Proteinuric Kidney Disease. Kidney Medicine, 2020, 2, 131-138.	2.0	2
142	Patient and caregiver perspectives on blood pressure in children with chronic kidney disease. Nephrology Dialysis Transplantation, 2022, 37, 1330-1339.	0.7	2
143	Neurodevelopmental Issues in Chronic Renal Disease. , 2008, , 733-741.		2
144	Child and caregiver perspectives on access to psychosocial and educational support in pediatric chronic kidney disease: a focus group study. Pediatric Nephrology, 2023, 38, 249-260.	1.7	2

#	Article	IF	Citations
145	Gluten-Free Diet in Childhood Difficult-to-Treat Nephrotic Syndrome: A Pilot Feasibility Study. Glomerular Diseases, 2022, 2, 176-183.	1.0	2
146	The clinical trial imperative. Pediatric Nephrology, 2005, 20, 5-9.	1.7	1
147	Focal segmental glomerulosclerosis. , 2012, , 212-216.		1
148	Focal Segmental Glomerulosclerosis. , 2014, , 170-175.		1
149	Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes. Pediatric Nephrology, 2022, 37, 1585-1595.	1.7	1
150	The authors reply. Pediatric Critical Care Medicine, 2014, 15, 918-919.	0.5	0
151	FC 023SAFETY OF BARDOXOLONE METHYL IN PEDIATRIC PATIENTS WITH ALPORT SYNDROME IN CARDINAL PHASE 3 TRIAL. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
152	Kidney in systemic lupus erythematosus and vasculitis. , 2006, , 245-260.		0
153	Neurological Effects and Cognitive Development. , 2012, , 581-592.		0